Sarcoma & GIST
Physician Resources
Ewing sarcoma: Professional resources from the National Cancer Institute
Physician Resources
Uterine sarcoma: Professional resources from the National Cancer Institute
From the Sarcoma Foundation of America
SFA's Medical Advisory Board
From the Sarcoma Foundation of America
Patient resources from SFA
From the Sarcoma Foundation of America
Apply for a Grant
From the Sarcoma Foundation of America
The Sarcoma Foundation of America: Funding research, advocating for patients
From the Journals
Dasatinib activity prominent in subset of GIST patients
The estimated rate of 6-month progression-free survival was 29% overall, though it was 50% in one biomarker-defined patient subset.
Clinical Trial Snapshot
Updates of ongoing clinical trials
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for...
Conference Coverage
Chemotherapy, metabolic pathway may affect CAR T-cell potential
Chemotherapy, especially with cyclophosphamide and doxorubicin, seems particularly toxic to T cells.
Case Reports
Anti-PD-1 therapy with nivolumab in the treatment of metastatic malignant PEComa
Perivascular epithelioid cell neoplasms (PEComas) are an uncommon class of tumors consisting on histology of perivascular epithelioid cells...
Case Reports
Tumor lysis syndrome in an adolescent with recurrence of abdominal rhabdomyosarcoma: A case report and literature review
IntroductionTumor lysis syndrome (TLS) is a life-threatening oncologic emergency that results when massive cell breakdown occurs either...